Why the study?
Does insulin detemir improve body composition and epicardial fat thickness compared to insulin glargine in insulin-naïve inadequately controlled patients with type 2 diabetes?
Does insulin detemir improve body composition and epicardial fat thickness compared to insulin glargine in insulin-naïve inadequately controlled patients with type 2 diabetes?
Initiation of insulin detemir in type 2 diabetes results in less weight and fat mass gain compared to insulin glargine, though epicardial fat thickness reduction is similar.
Answers are grounded in this paper and cite their sources.
May limit fat mass gain with detemir versus glargine at insulin start; leaves open differential epicardial fat effects in larger trials.
The aim of the study was to compare body composition and epicardial fat thickness changes in insulin-naïve inadequately controlled patients with type 2 diabetes following basal insulin initiation with detemir vs. glargine. Six-month, open-label, interventional randomized pilot study was conducted. Dual-energy X-ray absorptiometry and echocardiography were used to estimate the body composition and epicardial fat thickness respectively. Thirty-six patients in the detemir group and 20 in the glargine group completed the study. Study groups baseline characteristics were comparable. At 6 months, for similar glycemic control, those on detemir significantly gained less total weight (0.6±2.5 vs. 4.2±4.1 kg, p=0.004), total fat mass (0.9±2.2 vs. 2.9±2.4 kg, p=0.02), and truncal fat mass (0.8±1.5 vs. 2.1±1.7 kg, p=0.02), with a loss in truncal lean mass (- 0.8±1.9 kg vs. 0.3±1.7 kg; p=0.02). EFT significantly decreased from baseline in both group (detemir - 1.7±0.52-mm, glargine - 1.1±1.6-mm; p<0.05, without significant difference inter-groups). Within the detemir group, epicardial fat thickness change correlated with truncal fat and total fat mass changes (r=0.65, p=0.06 and r=0.60, p=0.07). In conclusion, detemir resulted in less fat mass gain, a trend for a more pronounced epicardial fat thickness reduction when compared with glargine.
No takes yet. Share an insight, caveat, or question.
Elisha et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: